| Identification | Back Directory | [Name]
Ethanone, 2-(3,5-dimethyl-1H-1,2,4-triazol-1-yl)-1-[(2R)-2-methyl-4-[4-[6-(5-methyl-1,2,4-oxadiazol-3-yl)-1H-benzimidazol-2-yl]-2-(trifluoromethyl)-5-thiazolyl]-1-piperazinyl]- | [CAS]
1449367-94-5 | [Synonyms]
ACT-672125
Ethanone, 2-(3,5-dimethyl-1H-1,2,4-triazol-1-yl)-1-[(2R)-2-methyl-4-[4-[6-(5-methyl-1,2,4-oxadiazol-3-yl)-1H-benzimidazol-2-yl]-2-(trifluoromethyl)-5-thiazolyl]-1-piperazinyl]- | [Molecular Formula]
C25H25F3N10O2S | [MOL File]
1449367-94-5.mol | [Molecular Weight]
586.59 |
| Hazard Information | Back Directory | [Description]
ACT-672125 is a Potent CXCR3 Antagonist with Therapeutic Potential in Autoimmune Diseases. ACT-672125 showed good physicochemical properties and safety profile. In a proof-of-mechanism model of lung inflammation, ACT-672125 inhibited the recruitment of CXCR3 expressing T cells into the inflamed lung in a dose-dependent manner. | [Uses]
ACT-672125 is a potent CXCR3 antagonist with IC50 value of 239 nM in human blood. ACT-672125 has activity for hERG with IC50 value of 18μM. ACT-672125 can be used for the research of autoimmune diseases[1]. | [References]
[1] Caroff E, et al. Design, Synthesis, and Pharmacological Evaluation of Benzimidazolo-thiazoles as Potent CXCR3 Antagonists with Therapeutic Potential in Autoimmune Diseases: Discovery of ACT-672125. J Med Chem. 2022 Sep 8;65(17):11533-11549. DOI:10.1021/acs.jmedchem.2c00676 |
|
|